Difference between revisions of "Non-Hodgkin lymphoma, pediatric"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "{{#lst:Section editor transclusions|peds}} <big>''This page contains studies that were specific to pediatric populations, who are generally treated based on risk-stratificatio...")
 
Line 50: Line 50:
 
COPADM: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>AD</u>'''riamycin (Doxorubicin), '''<u>M</u>'''ethotrexate
 
COPADM: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>AD</u>'''riamycin (Doxorubicin), '''<u>M</u>'''ethotrexate
 
===Protocol {{#subobject:39dc15|Variant=1}}===
 
===Protocol {{#subobject:39dc15|Variant=1}}===
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
−
!style="width: 33%"|Study
+
!style="width: 20%"|Study
−
!style="width: 33%"|Years of enrollment
+
!style="width: 20%"|Years of enrollment
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
 
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc1852229/ Patte et al. 2007 (FAB/LMB96)]
 
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc1852229/ Patte et al. 2007 (FAB/LMB96)]
 
|1996-2001
 
|1996-2001
 
|style="background-color:#91cf61"|Non-randomized portion of phase 3 RCT
 
|style="background-color:#91cf61"|Non-randomized portion of phase 3 RCT
 +
| style="background-color:#d3d3d3" |
 +
| style="background-color:#d3d3d3" |
 +
|-
 +
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7720281/ Minard-Colin et al. 2020 (Inter-B-NHL Ritux 2010)]
 +
|2011-2015
 +
| style="background-color:#1a9851" |Phase III (C)
 +
|[[#R-COPADM|R-COPADM]]
 +
| style="background-color:#d73027" |Inferior OS
 
|-
 
|-
 
|}
 
|}
−
''Note: It is not clear from the manuscript whether the cyclophosphamide was fractionated.''
+
''Note: It is not clear from Patte et al. 2007 whether the cyclophosphamide was fractionated.''
 
====Preceding treatment====
 
====Preceding treatment====
 
*[[#CVP|COP prephase]]
 
*[[#CVP|COP prephase]]
Line 79: Line 89:
  
 
====Subsequent treatment====
 
====Subsequent treatment====
−
*[[#COPADM|COPADM second inducation]]; reduced-dose versus [[#COPADM|COPADM second inducation]]; standard-dose
+
*[[#COPADM|COPADM second induction]]; reduced-dose versus [[#COPADM|COPADM second induction]]; standard-dose
  
 
===References===
 
===References===
 
# '''FAB/LMB96:''' Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007 Apr 1;109(7):2773-80. [https://doi.org/10.1182/blood-2006-07-036673 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc1852229/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/17132719/ PubMed] NCT00002757
 
# '''FAB/LMB96:''' Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007 Apr 1;109(7):2773-80. [https://doi.org/10.1182/blood-2006-07-036673 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc1852229/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/17132719/ PubMed] NCT00002757
 +
# '''Inter-B-NHL Ritux 2010:''' Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma; Children’s Oncology Group. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020 Jun 4;382(23):2207-2219. [https://doi.org/10.1056/nejmoa1915315 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7720281/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32492302/ PubMed] NCT01516580
 +
 +
==R-COPADM {{#subobject:bac173|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
R-COPADM: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>AD</u>'''riamycin (Doxorubicin), '''<u>M</u>'''ethotrexate
 +
===Protocol {{#subobject:avdc15|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Years of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7720281/ Minard-Colin et al. 2020 (Inter-B-NHL Ritux 2010)]
 +
|2011-2015
 +
| style="background-color:#1a9851" |Phase III (E-RT-esc)
 +
|[[#COPADM|COPADM]]
 +
| style="background-color:#1a9850" |Superior OS<br>OS36: 95.1% vs 87.3%<br>(HR 0.36, 95% CI 0.16-0.82)
 +
|-
 +
|}
 +
''Note: Only partial dosing information is available in the manuscript/supplement; dosing here is primarily based on FAB/LMB96.''
 +
====Preceding treatment====
 +
*[[#CVP|COP prephase]]
 +
====Targeted therapy====
 +
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days -2 & 1
 +
====Chemotherapy====
 +
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV twice per day on days 2 to 4 (total dose: 1500 mg/m<sup>2</sup>)
 +
*[[Vincristine (Oncovin)]] 2 mg/m<sup>2</sup> IV once on day 1
 +
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup>/day IV or PO on days 1 to 7
 +
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 2
 +
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1
 +
 +
====Supportive medications====
 +
*[[Folinic acid (Leucovorin)]]
 +
 +
====CNS prophylaxis====
 +
*[[Methotrexate (MTX)]] (dose not specified) IT once per day on days 2 & 6
 +
 +
'''One course'''
 +
 +
====Subsequent treatment====
 +
*[[#R-COPADM|R-COPADM second induction]]
 +
 +
===References===
 +
# '''Inter-B-NHL Ritux 2010:''' Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma; Children’s Oncology Group. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020 Jun 4;382(23):2207-2219. [https://doi.org/10.1056/nejmoa1915315 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7720281/ link to PMC article] '''contains partial protocol''' [https://pubmed.ncbi.nlm.nih.gov/32492302/ PubMed] NCT01516580
  
 
[[Category:Non-Hodgkin lymphoma regimens]]
 
[[Category:Non-Hodgkin lymphoma regimens]]

Revision as of 23:17, 3 December 2021

Section editor transclusions This page contains studies that were specific to pediatric populations, who are generally treated based on risk-stratification, not on the underlying histology. See individual trials for inclusion criteria.

3 regimens on this page
3 variants on this page


Untreated, pre-phase

CVP

back to top

CVP: Cyclophosphamide, Vincristine, Prednisone
COP: Cyclophosphamide, Oncovin (Vincristine), Prednisone

Regimen

Study Years of enrollment Evidence
Patte et al. 2007 (FAB/LMB96) 1996-2001 Non-randomized portion of phase 3 RCT

Chemotherapy

CNS prophylaxis

7-day course

Subsequent treatment

References

  1. FAB/LMB96: Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007 Apr 1;109(7):2773-80. link to original article link to PMC article contains verified protocol PubMed NCT00002757

Untreated, induction

COPADM

back to top

COPADM: Cyclophosphamide, Oncovin (Vincristine), Prednisone, ADriamycin (Doxorubicin), Methotrexate

Protocol

Study Years of enrollment Evidence Comparator Comparative Efficacy
Patte et al. 2007 (FAB/LMB96) 1996-2001 Non-randomized portion of phase 3 RCT
Minard-Colin et al. 2020 (Inter-B-NHL Ritux 2010) 2011-2015 Phase III (C) R-COPADM Inferior OS

Note: It is not clear from Patte et al. 2007 whether the cyclophosphamide was fractionated.

Preceding treatment

Chemotherapy

Supportive medications

CNS prophylaxis

One course

Subsequent treatment

References

  1. FAB/LMB96: Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007 Apr 1;109(7):2773-80. link to original article link to PMC article contains verified protocol PubMed NCT00002757
  2. Inter-B-NHL Ritux 2010: Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma; Children’s Oncology Group. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020 Jun 4;382(23):2207-2219. link to original article link to PMC article PubMed NCT01516580

R-COPADM

back to top

R-COPADM: Rituximab, Cyclophosphamide, Oncovin (Vincristine), Prednisone, ADriamycin (Doxorubicin), Methotrexate

Protocol

Study Years of enrollment Evidence Comparator Comparative Efficacy
Minard-Colin et al. 2020 (Inter-B-NHL Ritux 2010) 2011-2015 Phase III (E-RT-esc) COPADM Superior OS
OS36: 95.1% vs 87.3%
(HR 0.36, 95% CI 0.16-0.82)

Note: Only partial dosing information is available in the manuscript/supplement; dosing here is primarily based on FAB/LMB96.

Preceding treatment

Targeted therapy

Chemotherapy

Supportive medications

CNS prophylaxis

One course

Subsequent treatment

References

  1. Inter-B-NHL Ritux 2010: Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma; Children’s Oncology Group. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020 Jun 4;382(23):2207-2219. link to original article link to PMC article contains partial protocol PubMed NCT01516580
Retrieved from "https://hemonc.org/w/index.php?title=Non-Hodgkin_lymphoma,_pediatric&oldid=53332"